David Trafimow, a Distinguished Achievement professor of psychology at New Mexico State University, was recently selected to receive the prestigious Humboldt Research Award for 2026. Scott Brocato ...

A proposed function of TADs is to contribute to gene regulation by promoting chromatin interactions within a TAD and by suppressing interactions between TADs. Here, we directly probe the ...

In an interview, C. Ola Landgren, MD, PhD, delved into the details of the FDA's draft guidance on using MRD as a basis for ...

A broad low in Earth’s gravity field beneath Antarctica, known as the Antarctic geoid low, is not a sudden oddity. New reconstructions suggest it has persisted for about 70 million years and has been ...

Coinfection with RSV and RV is common in hospitalized children, but the impact of order of infection on disease severity remains unclear, according to Emily Schultz, MPhil, a PhD candidate in ...

Ongoing production and use of organophosphate tri-esters (tri-OPEs) have resulted in widespread environmental contamination, with levels occasionally ...

Heat does not have to reach record-breaking levels to change what happens in the womb. Across millions of births in sub-Saharan Africa and India, days with high maximum temperatures during pregnancy ...

Background/aims Posterior capsule opacification (PCO) is the most frequent long-term complication after cataract surgery, caused by proliferation of residual lens epithelial cells (LECs). Metformin, a ...

This study uses a Bayesian framework to characterize latent brain state dynamics associated with memory encoding and performance in children, as measured with functional magnetic resonance imaging.

Joining the call from Caris today are David Dean Halbert, our Founder, Chairman and CEO; David Spetzler, our President; Brian Brille, our Vice Chairman and EVP; Bobby Hill, our Chief Commercial ...

Q4 2025 Earnings Call February 24, 2026 4:30 PM ESTCompany ParticipantsChinmay Shukla - Senior Vice President of ...

In the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (axSpA), sonelokimab (SLK) demonstrated clinically meaningful benefit with 80+% of patients achieving ASAS40 by Week 12 Consistently, ...